From Prioritization to Universal Treatment: Successes and Challenges of Hepatitis C Virus Elimination in Italy

J Infect Dis. 2023 Sep 13;228(Suppl 3):S211-S220. doi: 10.1093/infdis/jiad038.

Abstract

Italy has had the highest prevalence of hepatitis C virus (HCV) infection and mortality from HCV-related liver cancer in Europe. Although direct-acting antivirals (DAA) were initially restricted to persons with advanced fibrosis, their use has since been extended to all infected individuals; more than 244 000 persons have been treated to date. HCV liver-related mortality is expected to decline by 75% by 2030, achieving the World Health Organization target for mortality. However, Italy risks failing to meet the overall goal of eliminating HCV infection by 2030. In this light, €71.5 million have been allocated for screening initially specific target populations (persons who inject drugs, prison inmates, and the 1969-1989 birth cohort). Herein, we outline the challenges and recommendations for how to move Italy toward HCV elimination, including expanding screening programs in other populations, increasing awareness through strategic communication, sustaining DAA access, and tailoring care models to meet the needs of key populations.

Keywords: HCV; HCV model of care; PWID; WHO elimination targets; global burden of disease; inmates; linkage to care; public health; screening; viral hepatitis elimination.

MeSH terms

  • Antiviral Agents / therapeutic use
  • Drug Users*
  • Hepacivirus
  • Hepatitis C* / drug therapy
  • Hepatitis C* / epidemiology
  • Hepatitis C* / prevention & control
  • Hepatitis C, Chronic*
  • Humans
  • Italy / epidemiology
  • Substance Abuse, Intravenous*

Substances

  • Antiviral Agents